Published in Thromb Haemost on March 01, 2001
Hereditary thrombophilia. Thromb J (2006) 1.08
The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis. J Vasc Surg (2012) 0.92
Fibrinolysis and the control of blood coagulation. Blood Rev (2014) 0.86
Immunohistochemical detection of uPA, tPA, and PAI-1 in a stasis-induced deep vein thrombosis model and its application to thrombus age estimation. Int J Legal Med (2012) 0.84
New combinational assay using soluble fibrin and d-dimer determinations: a promising strategy for identifying patients with suspected venous thromboembolism. PLoS One (2014) 0.81
Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study. PLoS One (2012) 0.76
The Occurrence of Thrombosis in Inflammatory Bowel Disease Is Reflected in the Clot Lysis Profile. Inflamm Bowel Dis (2015) 0.75
Conventional fibrinolytic assays for the evaluation of patients with venous thrombosis: don't bother. Thromb Haemost (2001) 0.75
t-plasminogen activator inhibitor-1 polymorphism in idiopathic pulmonary arterial hypertension. Indian J Hum Genet (2008) 0.75
Inhibition of PAI-1 Activity by Toddalolactone as a Mechanism for Promoting Blood Circulation and Removing Stasis by Chinese Herb Zanthoxylum nitidum var. tomentosum. Front Pharmacol (2017) 0.75
A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature (2000) 47.15
Life with 6000 genes. Science (1996) 41.51
Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science (1999) 36.25
Sequences that regulate the divergent GAL1-GAL10 promoter in Saccharomyces cerevisiae. Mol Cell Biol (1984) 20.61
The Burlington randomized trial of the nurse practitioner. N Engl J Med (1974) 17.02
A controlled trial of teaching critical appraisal of the clinical literature to medical students. JAMA (1987) 14.20
Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA (1999) 12.75
Making psychological theory useful for implementing evidence based practice: a consensus approach. Qual Saf Health Care (2005) 12.73
Controversy in counting and attributing events in clinical trials. N Engl J Med (1979) 7.25
A model fungal gene regulatory mechanism: the GAL genes of Saccharomyces cerevisiae. Microbiol Rev (1987) 7.00
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med (1995) 6.86
Identification of 5 types of Cryptosporidium parasites in children in Lima, Peru. J Infect Dis (2000) 6.71
Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol (1991) 6.55
Internists' attitudes about clinical practice guidelines. Ann Intern Med (1994) 6.55
Unintended changes in cognition, mood, and behavior arising from cell-based interventions for neurological conditions: ethical challenges. Am J Bioeth (2009) 6.13
Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ (1998) 6.07
Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation (1987) 5.73
National estimates of blood lead levels: United States, 1976-1980: association with selected demographic and socioeconomic factors. N Engl J Med (1982) 5.64
Travel and risk of venous thrombosis. Lancet (2000) 5.23
COMPASS: a complex of proteins associated with a trithorax-related SET domain protein. Proc Natl Acad Sci U S A (2001) 5.19
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med (1999) 5.14
The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell (1996) 5.10
Management of anticoagulation before and after elective surgery. N Engl J Med (1997) 5.10
Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med (1985) 5.09
Inability of trained nurses to perform basic life support. Br Med J (Clin Res Ed) (1987) 5.08
Jack Kevorkian: a medical hero. BMJ (1996) 4.87
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost (2000) 4.81
Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res (1996) 4.75
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med (1996) 4.70
Identification of a genetic locus for familial atrial fibrillation. N Engl J Med (1997) 4.66
Green fluorescent protein as a marker for gene expression and subcellular localization in budding yeast. Yeast (1996) 4.53
Second dose of measles, mumps, and rubella vaccine: questionnaire survey of health professionals. BMJ (2001) 4.50
Determining optimal therapy--randomized trials in individual patients. N Engl J Med (1986) 4.49
Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med (1997) 4.47
Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg (1997) 4.47
Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med (2001) 4.46
The Burlington randomized trial of the nurse practitioner: health outcomes of patients. Ann Intern Med (1974) 4.37
Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med (1998) 4.29
Synthesis of the yeast cell wall and its regulation. Annu Rev Biochem (1982) 4.26
Surveying Saccharomyces genomes to identify functional elements by comparative DNA sequence analysis. Genome Res (2001) 4.22
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation (2000) 4.12
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med (1996) 4.10
Do sick newborn infants benefit from participation in a randomized clinical trial? J Pediatr (1999) 3.98
Function and regulation of yeast hexose transporters. Microbiol Mol Biol Rev (1999) 3.96
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94
Simple method for elimination of aminoglycosides from serum to permit bioassay of other antimicrobial agents. Antimicrob Agents Chemother (1977) 3.91
Interventions to prevent weight gain: a systematic review of psychological models and behaviour change methods. Int J Obes Relat Metab Disord (2000) 3.90
Three different regulatory mechanisms enable yeast hexose transporter (HXT) genes to be induced by different levels of glucose. Mol Cell Biol (1995) 3.74
Predicting child abuse: signs of bonding failure in the maternity hospital. Br Med J (1977) 3.70
A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med (1993) 3.67
Publishing research supported by the tobacco industry. BMJ (1996) 3.65
The Drosophila ninaE gene encodes an opsin. Cell (1985) 3.65
Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med (1993) 3.61
Comparison of percutaneous and surgical tracheostomies. Chest (1996) 3.56
Two glucose transporters in Saccharomyces cerevisiae are glucose sensors that generate a signal for induction of gene expression. Proc Natl Acad Sci U S A (1996) 3.54
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51
Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet (2000) 3.50
Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science (1984) 3.47
Accuracy of clinical assessment of deep-vein thrombosis. Lancet (1995) 3.45
Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med (1996) 3.42
Identification of the DNA binding site for NGFI-B by genetic selection in yeast. Science (1991) 3.41
Disability: a model and measurement technique. Br J Prev Soc Med (1976) 3.41
Limitations of impedance plethysmography in the diagnosis of clinically suspected deep-vein thrombosis. Ann Intern Med (1993) 3.40
WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. Cell Mol Life Sci (2001) 3.38
A clinician's guide for conducting randomized trials in individual patients. CMAJ (1988) 3.35
Effect of bromhexine on ventilatory capacity in patients with a variety of chest diseases. Lancet (1969) 3.34
Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer--a meta-analysis. Clin Oncol (R Coll Radiol) (2002) 3.33
Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation (2001) 3.33
Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med (2000) 3.32
Verifying quality and safety in health informatics services. BMJ (2001) 3.31
Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen. Proc Natl Acad Sci U S A (1988) 3.25
Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation (1996) 3.23
Application of operant conditioning procedures to the behavior problems of an autistic child: a follow-up and extension. Behav Res Ther (1967) 3.23
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation (2001) 3.21
Mutations in the lactose operon caused by bacteriophage Mu. J Mol Biol (1972) 3.17
Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med (1982) 3.16
Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med (1998) 3.09
The cloned dopa decarboxylase gene is developmentally regulated when reintegrated into the Drosophila genome. Cell (1983) 3.08
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med (2001) 3.07
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med (1986) 3.00
Regulated expression of the GAL4 activator gene in yeast provides a sensitive genetic switch for glucose repression. Proc Natl Acad Sci U S A (1991) 3.00
Prevalence of myopia in the United States. Arch Ophthalmol (1983) 3.00